Drugs
Drugs
Rockwell Medical Run-Up Trade Follows Financing
Tickers in this article: RMTI KERX
One trader believes Rockwell shares will rise into clinical trial results expected in July.
05/21/13 - 08:00 AM EDT
MORE NEWS FOR DRUGS
| Company | Last | %CHNG | Volume |
|---|---|---|---|
| ZIOPHARM Oncology Inc. (ZIOP) | 2.62 | 29.75 | 16.77 M |
| Oragenics Inc (OGEN) | 3.35 | 21.38 | 0.02 M |
| Vanda Pharmaceuticals Inc. (VNDA) | 8.38 | 17.70 | 2.59 M |
| Valeant Pharmaceuticals International Inc (VRX) | 84.47 | 13.12 | 10.38 M |
| China Pharma Holding Inc. (CPHI) | 0.24 | 11.79 | 0.04 M |
| Oxygen Biotherapeutics Inc. (OXBT) | 4.48 | 7.95 | 0.00 M |
| Biosante Pharmaceuticals Inc. (BPAX) | 1.24 | 7.83 | 0.85 M |
| XenoPort Inc. (XNPT) | 5.78 | 7.24 | 0.72 M |
| Star Scientific Inc. (STSI) | 1.43 | 6.72 | 1.02 M |
| ADVENTRX Pharmaceuticals Inc. (ANX) | 0.73 | 5.80 | 0.61 M |
| Company | Last | %CHNG | Volume |
|---|---|---|---|
| Neuro-Hitech Incorporated (NHPI) | 0.01 | -15.79 | 0.01 M |
| GTx Inc. (GTXI) | 5.89 | -9.10 | 1.23 M |
| Bacterin International Holdings Inc. (BONE) | 0.68 | -8.24 | 0.17 M |
| Rexahn Pharmaceuticals Inc. (RNN) | 0.36 | -6.95 | 1.12 M |
| Redhill Biopharma Ltd (RDHL) | 10.70 | -6.88 | 0.00 M |
| Cardium Therapeutics Inc. (CXM) | 0.09 | -5.16 | 0.31 M |
| Rockwell Medical Inc (RMTI) | 3.78 | -4.55 | 0.77 M |
| Taro Pharmaceutical Industries Ltd (TARO) | 60.42 | -4.43 | 0.10 M |
| Venaxis Inc (APPY) | 1.30 | -4.41 | 11.40 M |
| MannKind Corporation (MNKD) | 6.55 | -4.38 | 13.79 M |
| Company | Last | %CHNG | Volume |
|---|---|---|---|
| Pfizer Inc (PFE) | 29.04 | -0.24 | 35.08 M |
| Elan Corp PLC (ELN) | 12.47 | 0.89 | 19.01 M |
| ZIOPHARM Oncology Inc. (ZIOP) | 2.62 | 29.75 | 16.77 M |
| Merck & Co Inc (MRK) | 47.16 | -0.36 | 15.80 M |
| MannKind Corporation (MNKD) | 6.55 | -4.38 | 13.79 M |
| Bristol-Myers Squibb Company (BMY) | 47.40 | 0.85 | 12.61 M |
| Warner Chilcott PLC (WCRX) | 19.96 | -0.20 | 11.45 M |
| Venaxis Inc (APPY) | 1.30 | -4.41 | 11.40 M |
| Johnson & Johnson (JNJ) | 86.82 | -0.45 | 10.39 M |
| Valeant Pharmaceuticals International Inc (VRX) | 84.47 | 13.12 | 10.38 M |
| Company | Last | %CHNG | Mkt Cap |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 86.82 | -0.45 | $245.0 B |
| Pfizer Inc (PFE) | 29.04 | -0.24 | $206.5 B |
| Novartis AG (NVS) | 74.36 | 0.73 | $181.4 B |
| Sanofi (SNY) | 54.86 | 0.55 | $146.3 B |
| Merck & Co Inc (MRK) | 47.16 | -0.36 | $142.9 B |
| GlaxoSmithKline PLC (GSK) | 52.97 | 0.46 | $142.3 B |
| Novo Nordisk A/S (NVO) | 168.64 | -0.17 | $92.9 B |
| Gilead Sciences Inc (GILD) | 55.81 | 0.59 | $84.6 B |
| Amgen Inc (AMGN) | 105.91 | 0.27 | $79.2 B |
| Bristol-Myers Squibb Company (BMY) | 47.40 | 0.85 | $77.2 B |
Featured Industry: Diversified Services
-
Berkshire Hathaway Operating Earnings Rise 42%
Warren Buffett's Berkshire Hathaway reported first-quarter operating earnings of $3.8 billion, heading into the company's annual meeting.
Verisk Analytics Inc. (VRSK): Today's Featured Diversified Services Laggard
Moody's Corporation (MCO): Today's Featured Diversified Services Winner
4 Big Stocks Ripe for a Sharp Pullback
Commit To Purchase H&R Block At $17, Earn 6.5%
Partner Headlines
-
Some IBD 50 Stocks Fall Below Buy Points
-
Circus ringmaster of the investment world
-
Stocks End Mixed With Lower Volume; Valeant Soars
-
Amgen, Inc. (AMGN): Today's Most Compelling Stock Buy
-
Stocks Turn Mixed In Dull Trade: Infoblox Surges On Earnings
-
Quiet Session Sees Small Losses; Valeant Surges On Deal Talk
-
Recession Is Coming
-
UPDATE: Deutsche Bank Initiates Coverage on Alnylam Pharmaceuticals with Buy Rating, $40 PT on Significant Long-Term Value Potential
-
NPS Pharma Prices Offering - Analyst Blog
-
Encouraging News for Peregrine Pharma - Analyst Blog
PR / BWire
-
Aegerion Pharmaceuticals Announces Webcast Of Investor Presentations At Upcoming Conferences
-
Royalty Pharma Discloses Acceptance Levels Of Original Offer For Elan Pursuant To Irish And United States Regulatory Requirements
-
Sangamo BioSciences Receives $6.4 Million Strategic Partnership Award From California Institute For Regenerative Medicine (CIRM) To Develop ZFP Therapeutic® For Beta-thalassemia
-
China Biologic Comments On The Proposed Shanghai RAAS Transaction
-
Sinovac Beijing Obtains China GMP Certificate Under The New GMP Guidelines
-
3SBio Inc. Announces Shareholders' Approval Of The Amended Merger Agreement
-
Vanda Pharmaceuticals Named The 2013 Life Science Firm Of The Year By The Tech Council Of Maryland
-
Venaxis Announces Pricing Of Offering Of Common Stock And Warrants
-
Amgen To Present At The Deutsche Bank 38th Annual Healthcare Conference
-
Neurocrine Biosciences To Present At The Deutsche Bank 38th Annual DbAccess Health Care Conference
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
Latest Market Update
04:42PM 05/24/13
NEW YORK (TheStreet) -- U.S. stocks posted their first weekly decline in five weeks on concern the Federal Reserve may wind down its stimulus program, while data showed weakness in China's manufacturing base, adding to doubts about the pace of the global economic recovery.
The S&P 500 finished down 0.05% to 1,649.61, off 1.07% for the week and posting its first three-day losing streak of the year. The weekly decline was the first since the week ended April 19.
TheDow Jones Industrial Average managed to squeeze into positive territory, settled up 0.06% to 15,303.10 and inching down 0.33% for the week while the Nasdaq closed down 0.01% to 3,459.14, off 1.14% for the week. ...
MoreBrokerage Partners
|
|
|
|
|
|
|
|
|
|
|
|